SEELOS THERAPEUTICS INC

GLD Partners Acquires Seelos Therapeutics Assets, Advancing Ketamine and Trehalose Programs to Phase 3 Trials

- GLD Partners, LP successfully acquired Seelos Therapeutics' late-stage ketamine and trehalose programs through a Chapter 11 bankruptcy process, positioning both assets for Phase 3 clinical development. - The ketamine program targets major depressive disorder and neuropsychiatric conditions, with GLD planning confirmatory Phase 3 pivotal trials aligned with FDA guidance. - The trehalose program represents a disease-modifying therapy for rare neurodegenerative and lysosomal storage disorders, advancing to adaptive Phase 2/3 studies with orphan drug designation potential. - The acquisition targets significant market opportunities, with the global MDD therapeutics market expected to exceed $15 billion annually by 2035 and trehalose applications in the multibillion-dollar rare disease treatment space.